Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD Sells 6,313 Shares of Cellebrite DI Ltd. $CLBT

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD decreased its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 1.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 373,768 shares of the company’s stock after selling 6,313 shares during the quarter. Cellebrite DI makes up 1.3% of Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD’s portfolio, making the stock its 26th largest position. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD owned 0.16% of Cellebrite DI worth $5,984,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CLBT. R Squared Ltd purchased a new position in Cellebrite DI during the 2nd quarter valued at about $189,000. Connors Investor Services Inc. increased its position in Cellebrite DI by 26.6% during the 2nd quarter. Connors Investor Services Inc. now owns 180,310 shares of the company’s stock valued at $2,885,000 after purchasing an additional 37,870 shares during the period. ARK Investment Management LLC increased its position in Cellebrite DI by 1.6% during the 2nd quarter. ARK Investment Management LLC now owns 86,063 shares of the company’s stock valued at $1,377,000 after purchasing an additional 1,363 shares during the period. Phoenix Financial Ltd. increased its position in Cellebrite DI by 153.5% during the 2nd quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company’s stock valued at $32,232,000 after purchasing an additional 1,219,958 shares during the period. Finally, Huntleigh Advisors Inc. increased its position in Cellebrite DI by 3.9% during the 2nd quarter. Huntleigh Advisors Inc. now owns 48,950 shares of the company’s stock valued at $783,000 after purchasing an additional 1,821 shares during the period. Institutional investors own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on CLBT. Lake Street Capital cut their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, August 15th. Wall Street Zen raised shares of Cellebrite DI from a “hold” rating to a “buy” rating in a research report on Friday, September 26th. Needham & Company LLC cut their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, August 14th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Cellebrite DI in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Cellebrite DI has an average rating of “Moderate Buy” and an average target price of $21.75.

Cellebrite DI Trading Up 3.6%

NASDAQ:CLBT opened at $18.42 on Friday. The company has a market cap of $4.41 billion, a PE ratio of -24.24, a P/E/G ratio of 3.23 and a beta of 1.29. Cellebrite DI Ltd. has a twelve month low of $13.10 and a twelve month high of $26.30. The company’s 50 day moving average is $17.56 and its two-hundred day moving average is $16.93.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Thursday, August 14th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.